IMMUNOVANT INC. - COMMON STOCK

Immunovant Announces Proposed Offering of $300 Million of Common Stock

26 سبتمبر 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

26 سبتمبر 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

25 سبتمبر 2023 22:01:32 بحسب Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

10 أغسطس 2023 06:00:01 بحسب Nasdaq GlobeNewswire

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

22 مايو 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

03 فبراير 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

07 نوفمبر 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

04 أكتوبر 2022 07:45:00 بحسب Nasdaq GlobeNewswire

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn  

28 سبتمبر 2022 09:45:00 بحسب Nasdaq GlobeNewswire

Immunovant to Present at Roivant Investor Day on September 28th

21 سبتمبر 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

09 سبتمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab

07 سبتمبر 2022 06:11:44 بحسب Nasdaq GlobeNewswire

Immunovant Announces Two New Development Programs for Batoclimab

07 سبتمبر 2022 05:30:00 بحسب Nasdaq GlobeNewswire

Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022

24 أغسطس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022

05 أغسطس 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022

08 يونيو 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022

06 يونيو 2022 15:47:47 بحسب Nasdaq GlobeNewswire

Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th

23 مايو 2022 15:05:00 بحسب Nasdaq GlobeNewswire

Immunovant to Present at the UBS Global Healthcare Conference on May 23rd

19 مايو 2022 15:05:00 بحسب Nasdaq GlobeNewswire

Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th

04 مايو 2022 07:00:02 بحسب Nasdaq GlobeNewswire